Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms (PLoS ONE (2017) 12:8 (e0183023) DOI: 10.1371/journal.pone.0183023);Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

PLoS ONE

Volumn 12, Issue 8, 2017, Pages

  Ilie, Marius ^a   Khambata Ford, Shirin ^b   Copie Bergman, Christiane ^c,d   Huang, Lingkang ^b   Juco, Jonathan ^b   Hofman, Veronique ^a   Hofman, Paul ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d FACULTÉ DE MÉDECINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 22C3; PROGRAMMED DEATH 1 LIGAND 1; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; AUTOMATIC SLIDE STAINER; AUTOMATION; BRONCHUS BIOPSY; CONTROLLED STUDY; GOLD STANDARD; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TONSIL; LUNG; LUNG TUMOR; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS;

EID: 85027298859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0186537     Document Type: Erratum

References (18)

1. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al; for the KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med 2015; 372 (21):2018–28. https://doi.org/10.1056/NEJMoa1501824 PMID: 25891174
2. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context 2015; 4:212289. https://doi.org/10.7573/dic.212289 PMID: 26576187
3. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015; 125(22):3393–400. https://doi.org/10.1182/blood-2015-02-567453 PMID: 25833961
4. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JE, Han J-Y, et al. Pembrolizumab versus doce-taxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; 387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7 PMID: 26712084
5. Keytruda [summary of product characteristics]. Hertfordshire, UK: Merck Sharpe & Dohme Limited; 2017.
6. Keytruda [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2017.
7. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al; for the KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 2016; 375(19):1823–33. https://doi.org/10.1056/NEJMoa1606774 PMID: 27718847
8. Dolled-Filhart M, Roach C, Toland G, Stanforth D, Jansson M, Lubiniecki GM, et al. Development of a companion diagnostic for pembrolizumab in non–small cell lung cancer using immunohistochemistry for programmed death ligand-1. Arch Pathol Lab Med 2016; 140(11):1243–9. https://doi.org/10.5858/arpa.2015-0542-OA PMID: 27552095
9. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non–small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016; 24(6):392–7. https://doi.org/10.1097/PAI.0000000000000408 PMID: 27333219
10. Ventana Medical Systems Inc. (2017) VENTANA PD-L1 (SP263) Assay. http://www.ventana.com/ventana-pd-l1-sp263-assay-2/.
11. Dako North American Inc. PD-L1 IHC 22C3 PharmDx. Carpinteria, CA: Dako North America Inc.; 2015.
12. Fargion S, Carney D, Mulshine J, Rosen S, Bunn P, Jewett P, et al. Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. Cancer Res 1986; 46(5):2633–38. PMID: 3008997
13. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol 2016; 2(1):46–54. https://doi.org/10.1001/jamaoncol.2015.3638 PMID: 26562159
14. Rehman JA, Han G, Carvajal-Hausdorf DE, Wasserman BE, Pelekanou V, Mani NL, et al. Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. Mod Pathol 2017; 30:340–9. https://doi.org/10.1038/modpathol.2016.186 PMID: 27834350
15. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016; 468(5):511–25. https://doi.org/10.1007/s00428-016-1910-4 PMID: 26915032
16. Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016; 29(10):1165–72. https://doi.org/10.1038/modpathol.2016.117 PMID: 27389313
17. Neuman T, London M, Kania-Almog J, Litvin A, Zohar Y, Fridel L, et al. A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana’s platform. J Thorac Oncol 2016; 11:1863–68. https://doi.org/10.1016/j.jtho.2016.08.146 PMID: 27664534
18. Røge R, Vyberg M, Nielsen S. Accurate PD-L1 protocols for non-small cell lung cancer can be developed for automated staining platforms with clone 22C3. Appl Immunohistochem Mol Morphol 2017; 25 (6):381–385. https://doi.org/10.1097/PAI.0000000000000534 PMID: 28697065